公开(公告)号：WO2023034290A1

公开(公告)日：2023-03-09

申请号：PCT/US2022/042023

申请日：2022-08-30

Applicant: INCYTE CORPORATION

Inventor： LI, Gencheng ,  YIN, Haolin ,  QI, Chao ,  WANG, Xiaozhao ,  YAO, Wenqing ,  HU, Bin ,  CARLSEN, Peter

IPC: C07D471/14 ,  C07D519/00 ,  A61P35/00 ,  A61K31/4375

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

公开(公告)号：WO2022204227A1

公开(公告)日：2022-09-29

申请号：PCT/US2022/021461

申请日：2022-03-23

Applicant: BIOAGE LABS, INC. ,  HITGEN, INC.

Inventor： HARTMAN, George ,  HE, Xu ,  DU, Jia ,  ZHANG, Lifang ,  HUMPHRIES, Paul ,  WILHELMSEN, Kevin Edward, Leif

IPC: A61P29/00 ,  C07D209/14 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.

公开(公告)号：WO2022072783A1

公开(公告)日：2022-04-07

申请号：PCT/US2021/053100

申请日：2021-10-01

Applicant: INCYTE CORPORATION

Inventor： HUANG, Taisheng ,  WANG, Xiaozhao ,  YAO, Wenqing

IPC: A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  C07D471/04 ,  A61K31/4985

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

公开(公告)号：WO2022047014A1

公开(公告)日：2022-03-03

申请号：PCT/US2021/047727

申请日：2021-08-26

Applicant: ALS THERAPY DEVELOPMENT INSTITUTE

Inventor： LUKASHEV, Matvey ,  PUSHECHNIKOV, Alexei ,  DEMIN, Peter ,  DENTON, Kyle

IPC: C07D213/53 ,  C07D401/04 ,  C07D413/04 ,  C07D207/24 ,  C07D207/09 ,  C07D211/26 ,  C07D231/12 ,  C07D263/32 ,  C07D265/28 ,  C07D277/64 ,  C07D307/52 ,  C07D307/81 ,  C07D405/06 ,  C07D407/06 ,  C07F1/08 ,  C07F9/54 ,  A61P25/28

Abstract: The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).

公开(公告)号：WO2022020342A1

公开(公告)日：2022-01-27

申请号：PCT/US2021/042355

申请日：2021-07-20

Applicant: NIDO BIOSCIENCES, INC.

Inventor： BAKARY-BARRY, Toure ,  GALLOP, Mark, Andrew ,  BARSANTI, Paul, Andrew

IPC: C07D491/052 ,  C07D471/04 ,  C07D413/14 ,  C07D498/04 ,  C07D413/04 ,  C07D401/04 ,  C07D405/14 ,  C07D401/14 ,  C07D403/04 ,  C07D417/04 ,  C07D403/14 ,  C07D513/04 ,  C07D487/08 ,  C07D405/04 ,  C07D409/04 ,  A61P25/00 ,  A61P33/00 ,  A61K31/497 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/404

Abstract: Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

公开(公告)号：WO2021127460A1

公开(公告)日：2021-06-24

申请号：PCT/US2020/066046

申请日：2020-12-18

Applicant: MERCK SHARP & DOHME CORP.

Inventor： JOSIEN, Hubert ,  LIU, Jian ,  TUCKER, Thomas Joseph ,  WALJI, Abbas M. ,  WOOD, Harold B.

IPC: A61K38/00 ,  A61P3/06 ,  C07K7/06 ,  C07K7/64 ,  C12N9/64

Abstract: Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein A, A1, A2, R1, R2 and R3 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

公开(公告)号：WO2021015841A1

公开(公告)日：2021-01-28

申请号：PCT/US2020/034242

申请日：2020-05-22

Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventor： RAINES, Ronald T. ,  WINDSOR, Ian William ,  GRAHAM, Brian James

IPC: A61K31/69 ,  C07F5/02 ,  C07F5/05

Abstract: Provided herein are boron-containing compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders.

公开(公告)号：WO2020257632A1

公开(公告)日：2020-12-24

申请号：PCT/US2020/038705

申请日：2020-06-19

Applicant: DANA-FARBER CANCER INSTITUTE, INC.

Inventor： GRAY, Nathanael S. ,  SCOTT, David A. ,  GERO, Thomas ,  ECK, Michael ,  HEPPNER, David ,  BEYETT, Tyler ,  TO, Ciric

IPC: A61K31/506 ,  A61K31/551 ,  A61P35/00

Abstract: The disclosure relates to compounds that act as an allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

公开(公告)号：WO2020068950A1

公开(公告)日：2020-04-02

申请号：PCT/US2019/052913

申请日：2019-09-25

Applicant: REGENACY PHARMACEUTICALS, LLC

Inventor： VAN DUZER, John, H. ,  MAZITSCHEK, Ralph ,  BLUM, Charles

IPC: A61K31/404 ,  C07D209/04 ,  C07D209/34 ,  C07D235/08 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12

Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

公开(公告)号：WO2020028254A1

公开(公告)日：2020-02-06

申请号：PCT/US2019/043920

申请日：2019-07-29

Applicant: SAREPTA THERAPEUTICS, INC. ,  MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventor： WOLFE, Justin M. ,  FADZEN, Colin M. ,  PENTELUTE, Bradley L. ,  HANSON, Gunnar J.

IPC: A61K31/712 ,  A61K31/713 ,  A61K47/64 ,  C12N15/113

Abstract: Provided herein are oligonucleotides, trimeric peptides, and peptide-oligonucleotide- conjugates. Also provided herein are methods of treating a muscle disease in a subject in need thereof, comprising administering to the subject oligonucleotides, trimeric peptides, and peptide-oligonucleotide-conjugates described herein.